Dapagliflozin in Patients with Chronic Kidney Disease

RCT (n=4304) found that regardless of presence/absence of diabetes, risk of composite of sustained decline in GFR≥ 50%, end-stage kidney disease, or death from renal or CV causes was significantly lower with dapagliflozin vs. placebo (9.2 vs. 14.5%; HR 0.61; 95% CI 0.51-0.72).

Source:

New England Journal of Medicine